- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04374136
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
March 18, 2024 updated by: Alector Inc.
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
Study completion marks the end of the open label extension period following the 96-week blinded portion of the study.
Study Type
Interventional
Enrollment (Estimated)
110
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Lead
- Phone Number: 650-826-2454
- Email: clinicaltrials@alector.com
Study Locations
-
-
-
Buenos Aires, Argentina, 2325
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
-
San Juan, Argentina, C1015ABR
- INECO Castaño
-
-
Ciudad Autónoma De BuenosAires
-
Retiro, Ciudad Autónoma De BuenosAires, Argentina, C1058AAJ
- CENydET S.R.L.
-
-
-
-
-
Box Hill, Australia, 3128
- Box Hill Hospital
-
Camperdown, Australia, 2050
- Royal Prince Alfred Hospital
-
Woodville, Australia
- The Queen Elizabeth Hospital
-
-
-
-
Vlaams Brabant
-
Leuven, Vlaams Brabant, Belgium, 3000
- UZ Leuven
-
-
-
-
-
London, Canada
- The University of Western Ontario
-
Toronto, Canada
- Sunnybrook Research Institute - University of Toronto
-
-
-
-
-
Bordeaux, France
- CHU de Bordeaux
-
Lille, France
- CHRU Lille
-
Paris, France
- Groupe Hospitalier Pitié Salpétrière
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, France, 31059
- CHU de Toulouse Hopital PURPAN
-
-
Seinne-Maritime
-
Rouen, Seinne-Maritime, France, 76000
- Hopital Charles Nicolle - Hospital
-
-
-
-
-
Köln, Germany, 50937
- Uniklinik Koln
-
Ulm, Germany
- Universitätsklinikum Ulm
-
-
-
-
Attica
-
Athens, Attica, Greece, 115 28
- Eginitio University General Hospital of Athens - 1st University Neurology Clinic
-
-
Evros
-
Alexandroupoli, Evros, Greece, 68100
- University General Hospital of Alexandroupolis - Department of Neurology
-
-
-
-
-
Baggiovara, Italy
- Nuovo Ospedale Civile S. Agostino-Estense di Baggiovara
-
Bologna, Italy, 40139
- IRCCS Istituto delle Scienze Neurologiche di Bologna
-
Brescia, Italy
- IRCCS - Centro S. Giovanni di Dio Fatebenefratelli
-
Brescia, Italy
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
-
Milano, Italy
- Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Milano, Italy
- Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
-
Tricase, Italy
- PIA Fondazione Panico
-
-
Emilia Romagna
-
Reggio Emilia, Emilia Romagna, Italy, 42122
- Azienda Unita Sanita Locale (ASL) di Reggio Emilia - IRCCS
-
-
Palermo
-
Cefalù, Palermo, Italy, 90015
- Fondazione Istituto G.Giglio
-
-
-
-
-
Rotterdam, Netherlands
- Erasmus MC
-
-
-
-
-
Coimbra, Portugal
- Centro Hospitalar e Universitario de Coimbra EPE
-
Lisboa, Portugal, 1649-035
- Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
-
Lisboa, Portugal
- Hospital Cuf Descobertas
-
Porto, Portugal, 4099-001
- Centro Hospitalar do Porto - Hospital de Santo António
-
-
-
-
-
Barcelona, Spain
- Hospital Clínic de Barcelona
-
Donostia-san Sebastián, Spain
- Hospital Universitario de Donostia
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Madrid, Spain, 28006
- Hospital Universitario de La Princesa
-
-
Cantabria
-
Santander, Cantabria, Spain, 39008
- Hospital Universitario Marqués de Valdecilla
-
-
-
-
-
Huddinge, Sweden
- Karolinska Universitetssjukhuset Huddinge - PPDS
-
-
-
-
-
Basel, Switzerland
- Felix Platter Spital
-
-
-
-
Balcova
-
Izmir, Balcova, Turkey, 35330
- Dokuz Eylul University
-
-
Fatih
-
Istanbul, Fatih, Turkey, 34093
- Istanbul University Medical Faculty
-
-
-
-
-
London, United Kingdom
- University College London
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Dignity Health
-
-
California
-
La Jolla, California, United States, 92093-0648
- University of California San Diego
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Emory University
-
-
Illinois
-
Evanston, Illinois, United States, 60611
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Health Neuroscience Center
-
-
Kansas
-
Fairway, Kansas, United States, 66205
- University of Kansas Alzheimer's Disease Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University School of Medicine
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Comprehensive Cancer Center - PPDS
-
-
New York
-
New York, New York, United States, 10032
- Irving Institute for Clinical and Translational Research
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-7025
- University of North Carolina At Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- University of Cincinnati Gardner Neuroscience Institute
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston Methodist Institute for Academic Medicine
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert and The Medical College of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Persons with a progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed with FTD.
- If symptomatic, one or more of the criteria for the diagnosis of possible behavioral variant FTD, or a diagnosis of Primary Progressive Aphasia.
- Study partner who consents to study participation and who cares for/visits the participant daily for at least 5 hours per week.
- Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
Exclusion Criteria:
- Dementia due to a condition other than FTD including, but not limited to, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia.
- Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
- Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.
- Females who are pregnant or breastfeeding, or planning to conceive within the study period.
- Any experimental vaccine or gene therapy.
- History of cancer within the last 5 years.
- Current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban).
- Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AL001
AL001 every 4 weeks
|
Administered via intravenous (IV) infusion
|
Placebo Comparator: Placebo
Placebo every 4 weeks
|
Administered via intravenous (IV) infusion
|
Experimental: Open label - AL001
AL001 every 4 weeks
|
Administered via intravenous (IV) infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB
Time Frame: Through study completion, on average up to 96 weeks
|
The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior & Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by a healthcare professional and based on individual ratings of the eight domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care, language and behavior.
Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3.
The 8 individual domain ratings, or "box scores", were added together to give the CDR® plus NACC FTLD-SB which ranges from 0-24.
Higher score indicates severe impairment.
|
Through study completion, on average up to 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinical Global Impression-Severity (CGI-S) Score
Time Frame: Baseline to 96 weeks
|
The CGI-S is used by a clinician to rate the severity of a participant's disease relative to the clinician's past experience with patients who have the same disease using an ordinal scale ranging from 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill patients.
Higher scores indicate worsening.
|
Baseline to 96 weeks
|
Change in Clinical Global Impression-Improvement (CGI-I) Score
Time Frame: Baseline to 96 weeks
|
The CGI-I is used by a clinician to rate how much a participant's disease has improved or worsened relative to baseline using an ordinal scale ranging from 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; and 7=very much worse.
Higher scores indicate worsening.
|
Baseline to 96 weeks
|
Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score
Time Frame: Baseline to 96 weeks
|
RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia.
RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests.
Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery.
Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15.
Higher scores indicate less impairment.
|
Baseline to 96 weeks
|
Pharmacodynamic Biomarkers
Time Frame: Baseline to 96 weeks
|
Change in magnetic resonance imaging and blood-based biomarkers and optional CSF biomarkers (neurofilament light chain and progranulin)
|
Baseline to 96 weeks
|
Evaluation of safety and tolerability of AL001: Incidence of adverse events
Time Frame: Baseline to 96 weeks
|
Incidence of adverse events
|
Baseline to 96 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optional Open-Label Extension
Time Frame: 96 weeks
|
Assess the long-term safety and tolerability of AL001 in participants who have completed 96 week of treatment
|
96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: TBD TBD
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 23, 2020
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
October 11, 2027
Study Registration Dates
First Submitted
April 23, 2020
First Submitted That Met QC Criteria
April 30, 2020
First Posted (Actual)
May 5, 2020
Study Record Updates
Last Update Posted (Actual)
March 19, 2024
Last Update Submitted That Met QC Criteria
March 18, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Aphasia
- Dementia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
Other Study ID Numbers
- AL001-3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frontotemporal Dementia
-
University of California, San FranciscoForest LaboratoriesCompletedSemantic Dementia | Frontal Lobe Dementia | Frontotemporal Lobe DementiaUnited States
-
Mayo ClinicRecruitingPrimary Progressive Aphasia | Behavioral Variant of Frontotemporal Dementia | Frontotemporal Dementia, Behavioral VariantUnited States
-
University of PennsylvaniaEnrolling by invitationFrontotemporal Degeneration | Frontotemporal Dementia | Frontotemporal Dementia, Behavioral Variant | FTDUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Massachusetts General HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Caregiver Stress Syndrome | Caregiver Burnout | Dementia, Mild | Dementia Moderate | Dementia Severe | Dementia FrontotemporalUnited States
-
BiogenCompletedFrontotemporal Dementia | Behavioral Variant Frontotemporal DementiaUnited States
-
Lawson Health Research InstituteRecruitingLewy Body Dementia (LBD) | Alzheimer Dementia (AD) | Dementia, FrontotemporalCanada
-
Vesper Biotechnologies ApSRecruitingDementia, FrontotemporalNetherlands
-
HealthPartners InstituteTerminatedFrontotemporal Dementia, Behavioral VariantUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); National Institute...CompletedFamilial Frontotemporal DementiaUnited States, Canada
Clinical Trials on AL001
-
Alector Inc.Active, not recruitingFrontotemporal DementiaCanada, United States, Germany, United Kingdom, Italy, Netherlands
-
Alector Inc.GlaxoSmithKlineEnrolling by invitationNeurodegenerative DiseasesCanada, United States, Belgium, France, Spain, Portugal, Germany, Italy, Netherlands, Sweden, United Kingdom
-
Alector Inc.TerminatedAmyotrophic Lateral SclerosisUnited States
-
Alector Inc.CompletedHealthy | Frontotemporal DementiaUnited States, Canada, United Kingdom
-
Zhongnan HospitalAkeso Biopharma Co., Ltd.Recruiting